Pfizer Halts China Vaccine Sales Due To License Expiry
This article was originally published in PharmAsia News
The largest foreign drug maker in the country has had to stop marketing its best-selling vaccine Prevenar, dealing a blow to a plan to bolster its vaccine portfolio.
You may also be interested in...
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.